Bio-Techne Corp (TECH)
NEUTRALFundamental
53
मूल्य
$72.34
मार्केट कैप
$11.27B
भाग 1 · कंपनी का मूल्य कितना है
अवलोकन
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
बैलेंस शीट और तरलता
राजस्व
$1.21B
पिछले 12 महीने (31/3/2026 तक)
शुद्ध आय
$110M
पिछले 12 महीने (31/3/2026 तक)
Free Cash Flow
$257M
कुल इक्विटी
$1.92B
कुल देनदारियाँ
$639M
Current Ratio
4.49
Interest Coverage
15.88
Debt/EBITDA
1.37
Earnings Per Share
राजस्व और शुद्ध आय
Free Cash Flow
आय विवरण
ऐतिहासिक विवरण
समय के साथ मार्जिन
समय के साथ ऋण
ऋण कितना भारी है
वृद्धि तालिका
वृद्धि — राजस्व
Fair Value अनुमान
Fair Value
$40.41
वर्तमान मूल्य
$72.34
Margin of Safety
-79.0%
Fair Value सीमा
$26.27 - $54.55
अनुमान विधियाँ
मूल्यांकन मेट्रिक्स
P/E Ratio
104.91
ROE
3.8%
P/B Ratio
5.44
P/FCF
42.04
Gross Margin
65.0%
ROIC
5.1%
लाभप्रदता Radar
Value Creation (Economic Moat)
ROIC
5.1%
WACC
11.4%
ROIC − WACC
-6.4 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamental विश्लेषण मानदंड
पास (15)
- Price CAGR 10.90%
- ROIC 5.1%
- Gross Margin 65.0%
- Debt/Equity ratio
- Operating Margin 12.7%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- Revenue Growth 5Y 10.6%
- Earnings Quality (OCF/NI) 2.69
- Share Dilution -0.3%
- Piotroski F-Score 5/9
फेल (11)
- EPS shows upward trend
- EPS CAGR -10.63%
- P/FCF 42.04
- P/B Ratio 5.44
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- ROE 5.4%
- Analyst Consensus 41% Buy
- Earnings Surprise avg 0.7%
- Net Margin Trend 9.0% vs 10.9%
अनुपलब्ध (2)
- Dividend Payout NaN%
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-Score
मिश्रित संकेत: कुछ क्षेत्रों पर ध्यान देना आवश्यक
Earnings गुणवत्ता
उच्च गुणवत्ता: earnings नकदी द्वारा समर्थित
शेयर Dilution
शेयर वापस खरीद रही है। शेयरधारक अनुकूल
प्रशासन
कार्यकारी टीम
| नाम | पद | आयु |
|---|---|---|
| Mr. Kim Kelderman | CEO, President & Director | 57 |
| Mr. William A. Geist | President of Protein Sciences Segment | 56 |
| Dr. Gary J. Latham Ph.D. | VP & CTO | - |
| Mr. David Clair C.F.A. | Vice President of Investor Relations | - |
Audit जोखिम
8
बोर्ड जोखिम
1
मुआवजा जोखिम
10
शेयरधारक अधिकार जोखिम
1
भाग 2 · कीमत और खरीदने का समय
यह हिस्सा यह नहीं बताता कि कंपनी अच्छी है या नहीं: यह तय करने में मदद करता है कि उसे कब खरीदें, जब फंडामेंटल आपको आश्वस्त कर चुके हों। इसमें: तकनीकी विश्लेषण, संभावना, ऐतिहासिक गिरावट, गामा एक्सपोज़र।
Latest News
Recent headlines for TECH, sourced from Markets Gazette.
- 6/15/2026POSITIVEActivist Investor Ananym Urges Bio-Techne to Consider Selling
Activist investor Ananym Capital Management has acquired a significant stake in Bio-Techne Corp., signaling a potential shift in the company's strategic direction. Ananym is actively urging the Bio-Techne board to initiate a comprehensive strategic review, with a primary focus on exploring a potential sale of the company. This development could lead to a substantial premium for shareholders if a sale materializes, as activist campaigns often aim to unlock shareholder value through such actions. Investors will be closely watching Bio-Techne's response and any subsequent strategic decisions.
- 3/13/2026NEGATIVEIs Bio-Techne Stock a Buy, Sell, or Hold After a Wealth Manager Dumps Its Entire Stake?
A significant wealth management firm has divested its entire stake in Bio-Techne Corporation, a developer of life sciences reagents and diagnostic solutions. While the specific reasons for the liquidation were not disclosed, the complete exit by a major investor raises concerns about potential headwinds or a reassessment of the company's future growth prospects. Investors will be closely watching for any further commentary from the firm or Bio-Techne management to understand the underlying drivers of this substantial sell-off, which could impact short-term sentiment and stock performance.
via Markets Gazette